Kim. And Officer. Thank Financial joining Jeffrey Chief good is Today, you, our Church, morning, everyone. me
Dr. Khursheed Anwer, Q&A will the during end addition, at Science Chief the available our session be of Officer prepared our remarks. In
previous have is on like and and non-viral opportunity. PlaCCine our multi-cistronic and pillars. as out expression growth As discussed modality an dependent on I'd of of PlaCCine calls, for licensing antigens. mono-or the to partnership the The development one our pathogen synthetic most proprietary of development I four spend is time during is Imunon's DNA today technology prophylactic our vaccines
preclinical next-generation being development It of in evaluated the for currently is studies vaccines.
platform as addressing modality with this technology a a advancing potential pathogens a important commercial interest. the made of next Vaccines as to exceptional Prophylactic have progress We solution features, both and product as
has our I most data asset anticipated. PlaCCine, some is will of which derisked and performing suggests we this recent been as with review preclinical
current Cells presented Summit preclinical Gordon protection a and XXXX results quarter, studies Vaccine and Technology workable enhanced PlaCCine Virus as that During persistence offering in breadth demonstrated address vaccines well Barcelona Conference variants, at immunity, robust that as vaccine from at limitations the temperatures. by Anwer characteristics and of in commercial cellular Research stability of emerging the Conference Dr. COVID-XX to the
responses post-vaccination specific over a commercial while responses antigen from the Importantly, spike than COVID-XX vaccine. were XX higher humoral persistent the a to months SARS-CoV-X period, immune PlaCCine vaccines after XX-month were mRNA T-cell
a improved study, response while within to single plateaued vaccination mouse another durability. dose a after increase XX the In of continued humoral the response commercial demonstrating mRNA PlaCCine days vaccine, time with to a over vaccine
greater to Especially stable We Tested our attributes hospitalization enough at will believe death. are that with temperature. month are at months at emphasize these for X DNA Vaccine refrigerated as important least in at recently, I refrigeration temperatures, and room pathogens commercial provide for distribution new XX how that and vaccine product. PlaCCine where shown have is or may protection there More challenges least networks. storage against, arise many we can't a reinfection, geographies
the into switch In and disease. in the of load be addressing addition, out spread to antigens multiple vaccine same our antigens rapidly ability should [ph] instrumental
across approach Beyond in Arenaviruses developing minute, or viruses, may a viruses the COVID-XX like booster development of vaccine [inaudible] at Imunon a will are PlaCCine which interested a come back be we the I next-generation beneficial. modality where interest, to data-based pathogens in of many
in and public fever, emerging stress pathogens. serious continue catch civilians. fevers are are against and prime and public most rates, potential Africa And manufacturers by regions Haemorrhagic at in West risk high lethal Ebola to the global facilities. of level U.S. these and commercial and health, health used there mobility mortality due haemorrhagic infectious handled X biological posed to Lassa, disease and up the spread are are and in need biosafety also such and that of existing cases viruses policy weapons spreads are or be to endemic to new threat several the with biodefense viruses which like classified worldwide vaccine as reoccurrence is Today, play the examples cause both which among Marburg
NHPs now IMNN-XXX, of vaccine turn this earlier the to pre-clinical to let's the Sanofi in as our the mice development COVID-XX the we studies that submitted booster. application FDA. pre-IND So, first next-generation designed All supported year and have
the us the written an gives are that FDA of XXXX am clinic on I received to enter We development the we in And have and soon well IND plan. and FDA. provided track clinical pleased the thereafter. tell the our comfort feedback data response that you submit first just encouraging Which from on to quarter
be plug-and-play strategy for our proposed also designed I/II IND is Phase principle for will FDA acceptable. the program, The proof a of The in provide to confirmed which humans. was that platform
for allows department confirms production simply the flexibility this and coding the So by of vaccine any the our antigen cassette. versatility the of modality, changing rapid which and
IMNN-XXX COVID-XX of FDA vaccine Omicron per variant as recommendation. is the the a Moderna candidate XBBX.X
FDA June fall XXXX. to Related make and recommendations discuss States remember this Committee Biological for SARS-Cov-X XX use in the of VRBPAC, United the beginning COVID-XX in Advisory Vaccines for for year that and the vaccine strains Products You the met updated on
a as Initial in has model, but shown Mpox, early only validity in COVID-XX to excellent the plug-and-play our as PlaCCine of could Plasmid know vaccine platform strength, data broad with monkeypox the suggests also appear work backbone, be confirm also the results, PlaCCine a using For applicability. DNA not useful
separate with in preclinical immunological generated hematological immunized the have And flu virus. with and an also we against and Mice at arenaviruses associated responses initiated work. XX X the vaccine Mpox responses three
universal of tumor-associated developing more our a application Last modalities two we mentioned produce prophylactic vaccines, quarter, technology to our cancer vaccines. as also I expansion cancer the logical that modality. called vaccine antigen concerns FixPlas DNA are of
to cancer We which have and IMNN-XXX. work melanoma, antigen a call develop initiated preclinical in tumor-associated TrpX [inaudible] vaccine we
antigens. modifier nucleic acid a against on based long-lasting and represents to a This selection optimization tumor antigen on along potent option single is the promising a strategy modality new and specific a with immune factor. to induce This immune response include
working our trip of completed in __ bivalent concept cost study, to potential proof have benefits, model, II vaccines. initial We NY-ESO-X trip multivalent II selecting announced
We tumor a very challenge, the with the and class improved survival. by growth the results delayed as tumor followed fixed happy vaccination, are
And neo-antigen vaccines. Now second fourth and in the the therapeutic studies tumor evaluating strategic are the early of of consisting vaccination followed a the completed discovery the will our of of be ongoing benefits cancer modality personalized for also by and vaccines in challenge IndiPlas year. our we half are
is on second ovarian Break set cancer Anderson, development. treatment in at advanced Foundation currently data that we Through combination DNA-based of looking now like full our Cancer more to to Phase last II IMNN-XXX, more in XXXX. and localized study, IMNN-XXX the I'd XXX touch to for interim, we mature Break of report Cancer is sites. Enrollment Recall our reached additional with of immunotherapy at and September, MD an expect patients, study half AVASTIN. remember, the as of This with the with add now open is working in Through you enrollment
products Alabama clinical and Hudsfeild we The outsourced to reduce facility This control existing our new the Biotechnology. facility unveiled infectious of the clinical Campus will of CGMP efficiencies Hudfeild of production new vaccines capability in costs therapies. June development manufacturers, materials R&D quality HudsonAlpha on the strategy lower facility immuno-oncology part for cancer complements testing our CGMP on Institute reliance for at and disease data-based our and site. support non-viral As
I/II cancer We with manufacturing Phase and facilitating out and fill-and-finish The components with studies FixPlas PLACCINE and capabilities site. plasmid activating infectious agents DNA are PLACCINE modalities. to formulation CDMO DNA carried JMP vaccine of partner support a at have built and DNA disease modality IndiPlas our DNA agents vaccine designed final own and GMP-grade to produce our key the our
engineered. Our or proteoms from now can select scientist the protein any be pathogen to human
conduct variety animal process. testing the Our allow disease run internal us the models. both, existing and control and also labs the in experiments have cost will a of ability capabilities These to to
results. upcoming the activities. a milestones our Church I'll I Jeff come and over will back Jeff. now, to will discuss who provide call of review turn and financial Then
